The earnings call highlighted significant revenue growth and positive feedback for new product initiatives, alongside increased costs related to expansion and legal challenges. Despite the increased net loss, the raised revenue guidance and strong market reception for new indications suggest a positive outlook.

Company Guidance

In the Ceribell Q2 2025 earnings call, the company provided an optimistic outlook, raising its full-year 2025 revenue guidance to a range of $85 million to $88 million, representing a 30% to 34% annual growth over 2024. The total revenue for the second quarter reached $21.2 million, reflecting a 38% increase compared to the same period last year. Ceribell reported 584 active accounts by the end of June 2025, with an increase of 26 new accounts during the quarter. Gross margin for the quarter was 88%, up from 86% the previous year. The company continues to invest in commercial infrastructure, aiming to expand coverage to 55 territories and anticipates significant growth in 2026 due to recent expansions in their sales force. Additionally, Ceribell is exploring further opportunities in the neonatal and delirium markets, with ongoing pilots and strategic initiatives, aiming to broaden their market presence and enhance their product offerings.

Strong Revenue Growth

Total revenue for Q2 2025 was $21.2 million, reflecting a 38% growth over the same period last year.

Increased Active Accounts

Ceribell reported 584 active accounts as of June 30, 2025, an increase of 26 active accounts during the second quarter.

Full Year Revenue Guidance Raised

Full year 2025 revenue guidance increased to $85 million to $88 million, up from the prior guidance of $83 million to $87 million.

High Gross Margin

Gross margin for Q2 2025 was 88%, compared to 86% in the prior year period.

Positive Reception for New Delirium Indication

The Ceribell product vision and prototypes for delirium received positive feedback at the American Delirium Society Conference.

Ceribell, Inc. (CBLL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CBLL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.42 / -	-1.85	―	―	―
Aug 05, 2025	2025 (Q2)	-0.40 / -0.38	-0.372	-2.15% (>-0.01)	―
May 08, 2025	2025 (Q1)	-0.41 / -0.36	―	―	―
Feb 25, 2025	2024 (Q4)	-0.32 / -0.40	―	―	―
Nov 12, 2024	2024 (Q3)	-0.34 / -1.85	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CBLL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$15.08	$12.78	-15.25%
May 08, 2025	$17.10	$15.97	-6.61%
Feb 25, 2025	$25.54	$25.20	-1.33%
Nov 12, 2024	$28.85	$27.88	-3.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ceribell, Inc. (CBLL) report earnings?

Ceribell, Inc. (CBLL) is schdueled to report earning on Nov 18, 2025, After Close (Confirmed).

What is Ceribell, Inc. (CBLL) earnings time?

Ceribell, Inc. (CBLL) earnings time is at Nov 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CBLL EPS forecast?

CBLL EPS forecast for the fiscal quarter 2025 (Q3) is -0.42.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing